Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine

Cariprazine is currently approved for the treatment of patients with schizophrenia (USA and EU), and for manic, depressive, and episodes with mixed features in bipolar I disorder (USA): several randomized controlled studies have also explored its efficacy in patients with major depressive disorder....

Descripción completa

Detalles Bibliográficos
Autores principales: Batinic, Borjanka, Ristic, Ivan, Zugic, Milica, Baldwin, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649660/
https://www.ncbi.nlm.nih.gov/pubmed/34887792
http://dx.doi.org/10.3389/fpsyt.2021.784370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649660/
https://www.ncbi.nlm.nih.gov/pubmed/34887792
http://dx.doi.org/10.3389/fpsyt.2021.784370

Ejemplares similares